Phase II/III study of the UB-612 vaccine against COVID-19
Latest Information Update: 05 Apr 2021
At a glance
- Drugs UB 612 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Dasa
- 01 Apr 2021 According to a COVAXX media release, the company expect to initiate this trial in Q2 2021.
- 14 Sep 2020 New trial record
- 09 Sep 2020 According to a COVAXX media release, under the agreement, COVAXX will provide Dasa with COVAXX's investigational UB-612 vaccine for the Phase II/III study in Brazil.